AGING LENS // BIOMARKER & LONGEVITY
MOTS-c mitochondrial aging: what the longevity and age-biomarker research shows
Levels that move with age, a longevity-linked DNA variant, performance restored in old mice, and a human cohort where the peptide tracked mortality risk.
The gist
Here is the MOTS-c mitochondrial aging story in plain terms. As bodies age, the power plants inside cells — the mitochondria — run less smoothly, and the signals they send change too. MOTS-c is one of those signals. Its levels rise and fall with age and fitness, a specific spelling change in mitochondrial DNA that alters MOTS-c has been tied to both longevity and diabetes risk, and in old mice, giving extra MOTS-c restored a surprising amount of physical capacity. In one group of very sick patients, blood MOTS-c even tracked survival. None of this means taking MOTS-c extends human life — it means the molecule is a real part of the aging conversation.
MOTS-c levels change with age and metabolic state
Mitochondrial-derived peptides, including MOTS-c, behave as age-dependent regulators of apoptosis (programmed cell death), insulin sensitivity, and inflammatory markers, and their circulating levels change with age [9]. In healthy aging men, skeletal-muscle MOTS-c expression was higher and correlated with myofiber-type composition, linking the body's own MOTS-c to human muscle aging [15].
The biomarker direction is not uniform. Serum MOTS-c was decreased in obese children and associated with vascular endothelial function [11], while muscle expression rose with age in men [15]. The molecule is mitochondrial-stress-responsive, so its level reflects metabolic context, which is why MOTS-c is studied as a candidate readout of mitochondrial and metabolic health rather than a simple up-or-down-with-age marker [6]. A 2022 review situates it within the broader mitochondrial-derived-peptide family in human aging and age-related disease [6].
Are circulating MOTS-c levels a biomarker of health or aging?
Are circulating MOTS-c levels a biomarker of health or aging?
Circulating and tissue MOTS-c change with age and metabolic state, and in a chronic-hemodialysis cohort serum MOTS-c was independently associated with mortality and cardiovascular events, supporting interest in it as a human biomarker [9][12]. In that prospective multicenter cohort of 94 dialysis patients (median 26.5-month follow-up), MOTS-c was independently associated with a composite of all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, p=0.05) and improved risk-model discrimination (ROC AUC 0.727 to 0.743) [12]. That is among the strongest human clinical-association data for the peptide — and it is an association in a specific patient group, not proof that changing MOTS-c changes outcomes.
The longevity variant: m.1382A>C
A specific mitochondrial DNA polymorphism, m.1382A>C, alters the MOTS-c peptide sequence and has been studied at the intersection of longevity and disease risk. It is pro-diabetogenic in certain populations, linking MOTS-c genetics to type 2 diabetes risk, and is prevalent in some East Asian groups [8]. An earlier commentary raised the hypothesis that MOTS-c genetics may play a role in exceptional human longevity [14].
This is the double edge of the aging story: the same variant that has been explored in the context of long life is associated with diabetes risk in some populations [8][14]. It is also a caution about uniformity — ancestry and genotype appear to shape MOTS-c biology, so findings in one population do not automatically transfer to another [8]. A 2023 diabetes-and-aging review summarizes the human-association and mechanistic data linking MOTS-c to metabolic and aging-related disease [10].
Performance restored in aged animals
The most striking aging-relevant intervention data come from mice. Exogenous MOTS-c significantly increased treadmill running capacity in aged (22-23.5-month) mice (P=0.000002), along with grip strength and gait, and exercise itself induced endogenous MOTS-c across young, middle-aged, and old animals [2]. The 2024 CK2-binding work helps explain the muscle side: tissue-specific CK2 modulation underlies effects on muscle glucose uptake and atrophy prevention [5].
These are mouse results. They make MOTS-c a serious candidate in aging biology — a circulating MOTS-c as a biomarker and a possible lever on age-related physical decline — but they are not evidence that supplementing MOTS-c improves healthspan in people, which would require the human trials that have not yet been completed [4].